MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company utilizes its proprietary Precision Endocrine Peptide (PEP) platform to design peptide prodrugs with extended time-action profiles, low peak-to-trough ratios, and less frequent dosing regimens. Its lead product candidate, canvuparatide (MBX 2109), is a parathyroid hormone peptide prodrug in Phase 3 development for the treatment of chronic hypoparathyroidism, designed to provide continuous hormone exposure with once-weekly administration. The company is also advancing an obesity portfolio, led by MBX 4291, a long-acting GLP-1/GIP co-agonist prodrug intended for potential once-monthly dosing, and imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist in Phase 2 development for post-bariatric hypoglycemia. MBX Biosciences serves patients in the United States and Europe, with regulatory designations from the U.S. Food and Drug Administration and the European Commission for its lead candidate. The company’s scientific co-founder, Dr. Richard DiMarchi, contributed foundational expertise in endocrine pharmacology and incretin agonist discovery to the platform’s development.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage mbxbio.com
Sector Healthcare IR page investors.mbxbio.com
Tags
peptide therapeutics, endocrine disorders, metabolic disorders, hypoparathyroidism, obesity, glp-1 agonists, prodrug technology, hormone replacement, clinical-stage, precision medicine, PEP, canvuparatide, MBX 2109, MBX 4291, imapextide, MBX 1416
Press page —

Metrics

Valuation  
Market cap $ 2.721B
Market cap (USD) $ 2.721B
P/E -18.09
PEG —
P/BV 5.75
P/S —
P/OCF -28.34
P/FCF -27.40
Dividend yield —
Turnover / mcap —
Returns  
ROE -27.8%
ROI -29.5%
ROIC -25.0%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 29
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022
Assets 385.144M 268.535M 84.18M 45.095M
Net profit -86.971M -61.922M -32.563M -26.135M
Free cash flow -81.878M -55.555M -32.107M -23.563M

Figure FY 2025 FY 2024 FY 2023 FY 2022
Share price 31.54 18.43 — —
Price performance 12m 0.71 — — —

Filed figures

Figure Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) 324,000 171,000 596,000
Cash and deposits (USD) 30.5M 49.4M 75.3M
Right-of-use assets (USD) 226,000 119,000 487,000
Cash flow detail
Operating cash flow (USD) -32M -54.7M -79.9M
Purchases of property, plant and equipment (USD) -129,000 -874,000 -1.93M
Change in payables (cash effect) (USD) 412,000 3.93M -2.46M
Share-based compensation (USD) 2.04M 5.22M 8.68M
Free cash flow (OCF - PPE - intangibles) (USD) -32.1M -55.6M -81.9M
Income detail
Research and development expense (USD) 28.5M 57.4M 79.2M
Total comprehensive income (USD) -32.5M -61.9M -86.7M
Comprehensive income to owners (USD) -32.5M -61.9M -86.7M
Reported Mar 17, 2025 Mar 17, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track for Q4 2026

Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug with potential for once-monthly dosing, accepted for presentation at ObesityWeek 2026

$481.6 million in cash and investments expected to support operations into 2029

CARMEL, Ind., and BURLINGTON, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate progress.

“The third quarter marked an important milestone for MBX with the initiation of our pivotal Phase 3 oPTimize trial of once-weekly canvuparatide, a potential best-in-class PTH replacement therapy,” said Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences.

Effective as of October 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Peter Radovich as a director of the Company. The Board determined that Mr. Radovich is independent under the applicable listing standards of The Nasdaq Stock Market (“Nasdaq”). Mr. Radovich has been designated as a Class I director to serve until the Company’s 2028 Annual Meeting of Stockholders, in accordance with the Company’s amended and restated by-laws and to serve thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation. In connection with the appointment, the Board set the size of the Board at eight directors.

In connection with his appointment as a non-employee director, Mr. Radovich will receive compensation, including an initial award of a non-qualified stock option to purchase 18,200 shares of the Company’s common stock, to be granted on the appointment date of October 20, 2026. In addition, Mr.

October 13, 2026

PDF Version

CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:

Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026 Format: Fireside Chat and 1x1 meetings Time: 11:00 – 11:25 a.m. EST Location: Boston, MA

UBS Global Biopharma Conference Date: Tuesday, November 17, 2026 Format: Fireside Chat and 1x1 meetings Time: 8:00 – 8:30 a.m. GMT Location: London, UK

Jefferies Global Healthcare Conference Date: Wednesday, November 18, 2026 Format: Fireside Chat and 1x1 meetings Time: 4:00 – 4:25 p.m. GMT Location: London, UK

The live webcasts can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.

About MBX Biosciences MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase 3; and an obesity portfolio that includes MBX 4291 in Phase 1, and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the Company website at www.mbxbio.com and follow us on LinkedIn and X.

Media Contact: George Shea We. Communications [email protected]

Investor Contact: Pete De Spain MBX Biosciences [email protected]

©2026 MBX Bio. All Rights Reserved.

©2026 MBX Bio. All Rights Reserved.

Website design by Mentus

Prompts

MBX Biosciences, Inc. (ticker MBX), listed in United States.

ETFs Holding MBX Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
OZEM 1.71% 18,003 $ 955.959K Nov 17, 2026
FMED 0.84% 7,000 $ 431.2K Aug 31, 2026
HRTS 0.56% 5,010 $ 308.616K Aug 31, 2026
BMED 0.41% 1,103 $ 58.591K Nov 16, 2026
FFSM 0.19% 42,630 $ 2.811M Jul 31, 2026
FSEV 0.16% 195 $ 10.764K Jun 30, 2026
VFMO 0.13% 41,490 $ 2.556M Aug 31, 2026
FESM 0.12% 121,515 $ 6.708M Jun 30, 2026
RESM 0.08% 50 $ 2,760.00 Jun 30, 2026
AVSC 0.02% 9,092 $ 482.967K Nov 16, 2026
DFAS 0.02% 121,739 $ 6.636M Nov 12, 2026
FSEG 0.02% 18 $ 993.60 Jun 30, 2026
MSSM 0.01% 1,314 $ 80.942K Aug 31, 2026
DFAU 0.00% 4,080 $ 222.401K Nov 12, 2026
DFUS 0.00% 5,882 $ 320.628K Nov 12, 2026
DFAC 0.00% 16,676 $ 909.009K Nov 12, 2026
DCOR 0.00% 1,774 $ 96.701K Nov 12, 2026
DFSU 0.00% 29 $ 1,580.79 Nov 12, 2026
AVSU 0.00% 14 $ 743.68 Nov 16, 2026